AI Article Synopsis
- Primary central nervous system lymphoma (PCNSL) is a rare type of lymphoma that primarily affects the brain and has a high relapse rate, making treatment challenging despite sensitivity to methotrexate-based regimens.
- New treatments like Bruton's tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy are emerging, but there is still uncertainty on whether to use BTKi alone or with traditional chemotherapy, and the effectiveness of CAR T therapy for PCNSL requires further investigation.
- The review covers recent advancements in understanding PCNSL, including its epidemiology, pathology, symptoms, diagnosis, and available treatment options.
Article Abstract
Primary central nervous system lymphoma (PCNSL) is a rare subtype of extra-nodal lymphoma. The high relapse rate of PCNSL remains a major challenge to the hematologists, even though patients exhibit high sensitivity to the methotrexate-based chemotherapeutic regimens. Recently, the advent of Bruton's tyrosine kinase inhibitor (BTKi) and CAR T treatment has made more treatment options available to a proportion of patients. However, whether BTKi monotherapy should be given alone or in combination with conventional chemotherapy is still a clinical question. The status of CAR T therapy for PCNSLs also needs to be elucidated. In this review, we summarized the latest progress on the epidemiology, pathology, clinical manifestation, diagnosis, and treatment options for PCNSLs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416460 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.689843 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!